TY - JOUR
T1 - Ifosfamide or trofosfamide in patients with intraocular lymphoma
AU - Jahnke, Kristoph
AU - Thiel, Eckhard
AU - Bechrakis, Nikolaos E.
AU - Willerding, Gregor
AU - Kraemer, Dale F.
AU - Fischer, Lars
AU - Korfel, Agnieszka
PY - 2009
Y1 - 2009
N2 - We evaluated response, progression-free survival (PFS), overall survival (OS), relapse patterns and long-term toxicity of intraocular lymphoma (IOL) patients treated with ifosfamide (IFO) or trofosfamide (TRO). In a prospective single center study, IFO or TRO were given to 10 patients with IOL. The median patient age was 73 (range 46-83) years. Six patients were pretreated with up to four treatment regimens for ocular or cerebral lymphoma, and four were therapy-naive. All patients responded, including nine complete remissions and one partial remission, with a median PFS of 18 (7-36) months. Seven patients relapsed: five in the eye and two in the brain. Median OS was 32 (7-37+) months. No long-term toxicity was observed in patients treated with IFO or TRO alone. IFO or TRO were active and well tolerated in this study. Thus, they may represent suitable combination partners for other cytostatics used for PCNSL and IOL treatment.
AB - We evaluated response, progression-free survival (PFS), overall survival (OS), relapse patterns and long-term toxicity of intraocular lymphoma (IOL) patients treated with ifosfamide (IFO) or trofosfamide (TRO). In a prospective single center study, IFO or TRO were given to 10 patients with IOL. The median patient age was 73 (range 46-83) years. Six patients were pretreated with up to four treatment regimens for ocular or cerebral lymphoma, and four were therapy-naive. All patients responded, including nine complete remissions and one partial remission, with a median PFS of 18 (7-36) months. Seven patients relapsed: five in the eye and two in the brain. Median OS was 32 (7-37+) months. No long-term toxicity was observed in patients treated with IFO or TRO alone. IFO or TRO were active and well tolerated in this study. Thus, they may represent suitable combination partners for other cytostatics used for PCNSL and IOL treatment.
KW - Ifosfamide
KW - Intraocular lymphoma
KW - Primary CNS lymphoma
KW - Trofosfamide
UR - http://www.scopus.com/inward/record.url?scp=67349239314&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67349239314&partnerID=8YFLogxK
U2 - 10.1007/s11060-008-9761-8
DO - 10.1007/s11060-008-9761-8
M3 - Article
C2 - 19099202
AN - SCOPUS:67349239314
SN - 0167-594X
VL - 93
SP - 213
EP - 217
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
IS - 2
ER -